ABCSG 64 / neoGRACE: Neoadjuvant Sacituzumab Govitecan versus Standard Chemotherapy in Endocrine-Nonresponsive ER+/HER2− Early Breast Cancer
Sponsor: Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group
Phase: 2
Disease: Estrogen receptor-positive HER2-negative early breast cancer, Endocrine-resistant breast carcinoma
EU trial number: 2025-520759-10-00
Population: Adults with operable invasive stage IIA–III ER-positive/HER2-negative breast adenocarcinoma, ECOG 0–1, demonstrating endocrine nonresponse (Ki-67 >10%) after approximately three weeks of neoadjuvant aromatase-inhibitor treatment.
Register Investigator Interest
Interested in offering this trial to suitable patients?